KR20210075705A - Composition comprising extracts of Orostachys japonicus as an active ingredient for preventing, alleviating or treating diabetes - Google Patents
Composition comprising extracts of Orostachys japonicus as an active ingredient for preventing, alleviating or treating diabetes Download PDFInfo
- Publication number
- KR20210075705A KR20210075705A KR1020190167097A KR20190167097A KR20210075705A KR 20210075705 A KR20210075705 A KR 20210075705A KR 1020190167097 A KR1020190167097 A KR 1020190167097A KR 20190167097 A KR20190167097 A KR 20190167097A KR 20210075705 A KR20210075705 A KR 20210075705A
- Authority
- KR
- South Korea
- Prior art keywords
- wasong
- confirmed
- extract
- alcohol extract
- hot water
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 110
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 239000004480 active ingredient Substances 0.000 title claims description 6
- 241000304370 Orostachys Species 0.000 title description 2
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 23
- 241000196324 Embryophyta Species 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 241001165529 Orostachys japonica Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- 230000014509 gene expression Effects 0.000 description 39
- 210000004185 liver Anatomy 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 230000003247 decreasing effect Effects 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 238000005259 measurement Methods 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 238000011888 autopsy Methods 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 206010067125 Liver injury Diseases 0.000 description 8
- 231100000234 hepatic damage Toxicity 0.000 description 8
- 230000008818 liver damage Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000010835 comparative analysis Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000004110 gluconeogenesis Effects 0.000 description 6
- 108091005995 glycated hemoglobin Proteins 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 5
- 101710099339 Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 230000003178 anti-diabetic effect Effects 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 102000004311 liver X receptors Human genes 0.000 description 4
- 108090000865 liver X receptors Proteins 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 3
- 102100021641 Acetyl-CoA carboxylase 2 Human genes 0.000 description 3
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 3
- 101000677540 Homo sapiens Acetyl-CoA carboxylase 2 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000023984 PPAR alpha Human genes 0.000 description 3
- 108091006300 SLC2A4 Proteins 0.000 description 3
- 102100033939 Solute carrier family 2, facilitated glucose transporter member 4 Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
- 102000018616 Apolipoproteins B Human genes 0.000 description 2
- 108010027006 Apolipoproteins B Proteins 0.000 description 2
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 2
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 description 2
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 2
- 108091006299 SLC2A2 Proteins 0.000 description 2
- 102100023537 Solute carrier family 2, facilitated glucose transporter member 2 Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 108010070004 glucose receptor Proteins 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 1
- 101100041816 Homo sapiens SCD gene Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 1
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 101150097713 SCD1 gene Proteins 0.000 description 1
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- 108010074438 Sterol Regulatory Element Binding Protein 2 Proteins 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- 102100026841 Sterol regulatory element-binding protein 2 Human genes 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/23—Removal of unwanted matter, e.g. deodorisation or detoxification by extraction with solvents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 와송 추출물을 유효성분으로 함유하여 당뇨를 예방, 개선하거나 치료하는 용도의 조성물에 관한 것이다.The present invention relates to a composition for preventing, improving or treating diabetes by containing a Wasong extract as an active ingredient.
당뇨병은 탄수화물 대사에 작용하는 인슐린(insulin)의 작용이 정상적으로 이루어지지 않아 일어나는 내분비 장애의 가장 대표적인 질병으로, 주로 소아에서 발생하며 췌장 (pancreas)의 인슐린 분비가 감소에 의한 제1형 당뇨병 및 성인에서 주로 발생하며 인체 각 조직이 인슐린에 대해 무반응성의 인슐린 저항성 증상을 나타내는 제2형 당뇨병으로 분류된다.Diabetes mellitus is the most representative disease of endocrine disorders caused by the failure of insulin, which acts on carbohydrate metabolism, to function normally. It occurs mainly and is classified as
당뇨병의 주된 치료제로서는 설포닐우레아 (sulfonylureas)계 약물, 비구아니드 (biguanides)계 등의 경구로 섭취하는 혈당강하제와 DNA 재조합법에 의하여 얻은 인슐린 등이 사용되고 있다. 하지만 이런 약물들은 저혈당증 유발, 신장독성, 유산증, 설사와 배탈, 면역거부반응 등 많은 부작용을 가지고있어 부작용이 적은 천연물을 이용하려는 연구가 활발해지고 있다.As the main therapeutic agents for diabetes, sulfonylureas-based drugs, biguanides-based orally ingested hypoglycemic agents, and insulin obtained by DNA recombination are used. However, these drugs have many side effects, such as hypoglycemia induction, renal toxicity, lactic acidosis, diarrhea and upset stomach, and immune rejection.
한편, 와송(瓦松)은 바위솔(Orostachys japonicus A. Berger)이라 하며 일명 암송(岩松), 옥송(屋松), 작엽하초(昨葉何草) 등으로 불리는 돌나물과(Crassulaceae)의 다년생 초본 식물로서 한방에서 해열, 소종, 지혈, 이습 등에 사용되며[金在佶, 1984, 原色天然藥物大事典(上卷), 南山堂, 서울, p.447] 민간요법으로 암치료에도 많이 이용되고 있다[배성식,1990, 한방과 건강, 1, 26].On the other hand, Wasong (瓦松) is called Orostachys japonicus A. Berger, and is a perennial herbaceous plant of the Crassulaceae family, also called cypress (岩松), jade pine (屋松), and sedumaceae (昨葉何草). It is used in oriental medicine for antipyretic, epilepsy, hemostasis, and eczema [金在佶, 1984, 原色天然藥物大事典(上卷), Namsan堂, Seoul, p.447] and is widely used in cancer treatment as folk remedies [ Bae Seong-sik, 1990, Oriental Medicine and Health, 1, 26].
이 식물은 바위 곁에 붙어서 자라는 육질의 다년생 초본이지만 꽃이 피고 열매를 맺으면 고사하는 특징이 있다. 근생엽은 로제트형으로 퍼지며 끝이 굳어져서 가시처럼 되고 원줄기에 잎이 달리며 엽병이 없고 여름철에 나오는 근생엽과 더불어 끝이 굳어지지 않고 다만 뾰족해질 뿐이며 피침형으로서 녹색이지만 자주색 또는 분을 칠한 듯한 백색인것도 있다. 꽃은 9월에 피고 백색이며 총상화서는 길이 6∼15cm로서 화병이 없는 꽃이 밀착하고 포는 피침형이며 끝이 뾰족하다. 꽃받침은 5개로서 피침형이고 녹색이며 꽃잎도 5개로서 피침형 예두이고 길이 6mm 정도이다. 수술은10개이며 꽃잎보다 길고 자방은 5개이며 화분은 적색이지만 점차 흑색으로 된다[이창복, 1979, 大韓植物圖鑑, 鄕文社 서울, p.402]. 와송은 여름부터 가을에 걸쳐 채취하며 뿌리를 제거한 전초(全草)를 햇볕에 말려 약용으로 한다[金在佶, 1984, 原色天然藥物大事典(上卷), 南山堂, 서울, p.447].Although this plant is a fleshy perennial herb that grows by attaching to rocks, it has a characteristic that it dies when flowers bloom and bear fruit. The rosette-shaped leaves spread in a rosette-like shape and become thorn-like with leaves hanging on the main stem, without petioles. Together with the rosette leaves in summer, the end does not harden but only becomes sharp. It is lanceolate, green, but purple or white. have. The flowers bloom in September and are white, and the raceme is 6-15cm long, and the flowers without a vase are closely attached, and the bracts are lanceolate and have a sharp tip. The sepals are 5, lanceolate, green, and 5 petals, lanceolate acute, about 6mm long. Stamens are 10, longer than petals, have 5 ovaries, and the pollen is red, but gradually turns black [Changbok Lee, 1979, Daehanmunsa Seoul, p.402]. Wasong is harvested from summer to autumn, and the whole plant with its roots removed is dried in the sun for medicinal use [金在佶, 1984, 原色天然藥物大事典(上卷), Namsan堂, Seoul, p.447] .
와송을 본초학적으로 문헌을 통하여 고찰하여 보면 당본초(唐本草)에는 구중(口中)의 건조(乾燥)와 통증에 사용한다고 하며 본초강목에는 대장하혈에 물로 추출하여 복용하고, 모든 상처에 도포하면 수렴 효과가 있다고 하며 본초재신에는 백독(百毒)을 치료하고 종(腫)을 소실시키며 분류초약성에는 치질의 종통출혈을 다스리는 데는 약초를 전액(煎液)으로하여 세척한다고 하며 본초재신에는 창(瘡)과 유(癒)에 효과가 있다고 한다[上海科學技術出版社 小學館編 ;中藥大事典, 小學館, 1985, p.526].According to the herbalist review of Wasong in the literature, it is said that Dangboncho (唐本草) is used for dry mouth and pain (乾燥), extracting water from the subarachnoid blood of the large intestine and taking it, and applying it to all wounds. It is said to have an astringent effect, and herbal remedies are said to treat white poison (百毒) and eliminate bells (腫). It is said to be effective against (瘡) and oil (癒) [上海科学技術出版社 小学館編; 中藥大事典, 小学館, 1985, p.526].
이와 같은 와송은 피부 주름 개선효과(특허문헌 1), 바이오필름을 억제하는 효과(특허문헌 2)가 있음이 알려져 있다. It is known that such a wasong has an effect of improving skin wrinkles (Patent Document 1) and suppressing a biofilm (Patent Document 2).
본 출원의 발명자들은 위와 같은 와송 추출물이 혈당을 낮춤으로써 당뇨를 개선하는데 효능이 있는 것을 발견하고, 본 발명을 완성하였다. The inventors of the present application found that the Wasong extract as above is effective in improving diabetes by lowering blood sugar, and completed the present invention.
본 발명에서 해결하고자 하는 과제는 식물 기반 추출물을 이용하여 당뇨를 개선, 예방 및 치료할 수 있는 조성물을 제공하는 것이다.An object to be solved in the present invention is to provide a composition capable of improving, preventing and treating diabetes using a plant-based extract.
위와 같은 과제를 해결하기 위한 본 발명에 따른 조성물은 와송 추출물을 유효성분으로 함유하여 당뇨를 예방하거나 개선하는 용도의 식품 조성물을 제공하는 것을 기술적 특징으로 한다. The composition according to the present invention for solving the above problems is characterized in that it contains a Wasong extract as an active ingredient to provide a food composition for preventing or improving diabetes.
위와 같은 과제를 해결하기 위한 본 발명에 따른 조성물은 와송 추출물을 유효성분으로 함유하여 당뇨를 예방하거나 치료하는 용도의 약학 조성물을 제공하는 것을 기술적 특징으로 한다. The composition according to the present invention for solving the above problems is characterized in that it contains a Wasong extract as an active ingredient to provide a pharmaceutical composition for preventing or treating diabetes.
본 발명에 따른 조성물은 식물을 이용하여 인체 내 부작용을 최소화시킬 수 있고, 혈당 수치를 정상범위로 낮춤과 동시에 췌장베타세포를 활성시킴으로써 효율적으로 당뇨병을 예방, 개선 또는 치료할 수 있다.The composition according to the present invention can minimize side effects in the human body using plants, and can effectively prevent, improve or treat diabetes by lowering blood sugar levels to a normal range and activating pancreatic beta cells at the same time.
도 1은 피하 및 복강 내 지방조직 부검 결과 사진(와송 주정추출물 기준)
도 2는 간의 지방조직 부검 결과 사진(와송 주정추출물 기준)
도 3은 피하 및 복강 내 지방조직 부검 결과 사진(와송 열수추출물 기준)
도 4는 간의 지방조직 부검 결과 사진(와송 열수추출물 기준)
도 5는 주수별 체중 측정 결과를 나타내는 그래프(와송 주정추출물 기준)
도 6은 부검 후 체중 측정 결과를 나타내는 그래프(와송 주정추출물 기준)
도 7은 부검 후 간 무게, 간 무게/체중 비율 및 신장 무게 결과를 나타내는 그래프(와송 주정추출물 기준)
도 8은 주수별 체중 측정 결과를 나타내는 그래프(와송 열수추출물 기준)
도 9는 부검 후 체중 측정 결과를 나타내는 그래프(와송 열수추출물 기준)
도 10은 부검 후 간 무게, 간 무게/체중 비율 및 신장 무게 결과를 나타내는 그래프(와송 열수추출물 기준)
도 11은 혈당 및 당화혈색소의 측정 결과를 나타내는 그래프(와송 주정추출물 기준)
도 12는 혈당 및 당화혈색소의 측정 결과를 나타내는 그래프(와송 열수추출물 기준)
도 13은 경구 당 부하검사 결과를 나타내는 그래프(와송 주정추출물 기준)
도 14는 경구 당 부하검사 결과를 나타내는 그래프(와송 열수추출물 기준)
도 15는 간 손상 수치(ALT, AST, BUN) 측정 결과를 나타내는 그래프(와송 주정추출물 기준)
도 16은 간 손상 수치(ALT, AST, BUN) 측정 결과를 나타내는 그래프(와송 열수추출물 기준)
도 17은 중성지방 및 총 콜레스테롤 측정 결과를 나타내는 그래프(와송 주정추출물 기준)
도 18은 중성지방 및 총 콜레스테롤 측정 결과를 나타내는 그래프(와송 열수추출물 기준)
도 19는 간의 H&E 염색 결과를 나타내는 사진(와송 주정추출물 기준)
도 20은 간의 H&E 염색 결과를 나타내는 사진(와송 열수추출물 기준)
도 21은 췌장의 H&E 염색 결과를 나타내는 사진(와송 주정추출물 기준)
도 22는 신장의 H&E 염색 결과를 나타내는 사진(와송 주정추출물 기준)
도 23은 신장의 H&E 염색 결과를 나타내는 사진(와송 열수추출물 기준)
도 24는 지질대사 및 지질생합성 관련 유전자의 발현 결과를 나타내는 그래프(와송 주정추출물 기준)
도 25는 지질대사 및 지질생합성 관련 유전자의 발현 결과를 나타내는 그래프(와송 열수추출물 기준)
도 26은 염증 관련 유전자의 발현 결과를 나타내는 그래프(와송 주정추출물 기준)
도 27은 당 수용체 및 당 신생합성 관련 유전자의 발현 결과를 나타내는 그래프(와송 주정추출물 기준)
도 28은 당 수용체 및 당 신생합성 관련 유전자의 발현 결과를 나타내는 그래프(와송 열수추출물 기준)
도 29는 인슐린 저항성 실험모델의 유전자 발현 분석 결과를 나타낸 그래프(와송 주정추출물 기준)1 is a subcutaneous and intra-abdominal adipose tissue autopsy result photograph (based on wasong alcohol extract)
Figure 2 is a picture of the autopsy result of adipose tissue of the liver (based on wasong alcohol extract)
3 is a subcutaneous and intra-abdominal adipose tissue autopsy result photograph (based on wasong hot water extract)
4 is a picture of the autopsy result of adipose tissue of the liver (based on wasong hot water extract)
Figure 5 is a graph showing the weight measurement results by number of weeks (based on wasong alcohol extract)
6 is a graph showing the weight measurement results after autopsy (based on wasong alcohol extract)
7 is a graph showing the liver weight, liver weight / weight ratio, and kidney weight results after autopsy (based on wasong alcohol extract)
8 is a graph showing the weight measurement results for each week (based on wasong hot water extract)
9 is a graph showing the weight measurement results after autopsy (based on wasong hot water extract)
10 is a graph showing the liver weight, liver weight / weight ratio, and kidney weight results after autopsy (based on wasong hot water extract)
11 is a graph showing the measurement results of blood sugar and glycated hemoglobin (based on wasong alcohol extract)
12 is a graph showing the measurement results of blood sugar and glycated hemoglobin (based on wasong hot water extract)
13 is a graph showing the results of an oral glucose tolerance test (based on wasong alcohol extract)
14 is a graph showing the results of the oral glucose tolerance test (based on wasong hot water extract)
15 is a graph showing the measurement results of liver damage levels (ALT, AST, BUN) (based on wasong alcohol extract)
16 is a graph showing the measurement results of liver damage levels (ALT, AST, BUN) (based on wasong hot water extract)
17 is a graph showing the measurement results of triglycerides and total cholesterol (based on wasong alcohol extract)
18 is a graph showing the measurement results of triglycerides and total cholesterol (based on wasong hot water extract)
19 is a photograph showing the results of H & E staining of the liver (based on wasong alcohol extract)
20 is a photograph showing the results of H & E staining of the liver (based on wasong hot water extract)
Figure 21 is a photograph showing the results of H & E staining of the pancreas (based on wasong alcohol extract)
22 is a photograph showing the result of H & E staining of the kidney (based on wasong alcohol extract)
23 is a photograph showing the result of H & E staining of the kidney (based on wasong hot water extract)
24 is a graph showing the expression results of genes related to lipid metabolism and lipid biosynthesis (based on wasong alcohol extract)
25 is a graph showing the expression results of lipid metabolism and lipid biosynthesis related genes (based on wasong hot water extract)
26 is a graph showing the expression results of inflammation-related genes (based on wasong alcohol extract)
27 is a graph showing the expression results of glucose receptors and glucose neosynthesis-related genes (based on Wasong alcohol extract)
28 is a graph showing the expression results of glucose receptors and glucose neosynthesis-related genes (based on wasong hot water extract)
29 is a graph showing the results of gene expression analysis of the insulin resistance experimental model (based on wasong alcohol extract)
본 명세서 및 청구범위에 사용된 용어나 단어는 "발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙"에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야지, 통상적이거나 사전적인 의미로 한정해서 해석되서는 안 된다.The terms or words used in the present specification and claims conform to the technical idea of the present invention based on the "principle that the inventor can appropriately define the concept of a term in order to best describe his invention" It should be interpreted as the meaning and concept that
따라서 본 명세서에 기재된 실시예와 도면에 도시된 구성은 본 발명의 가장 바람직한 실시예에 불과할 뿐이고, 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형 예들이 있을 수 있음을 이해해야 한다.Therefore, the embodiments described in this specification and the configurations shown in the drawings are only the most preferred embodiments of the present invention, and do not represent all the technical ideas of the present invention, so various equivalents that can replace them at the time of the present application It should be understood that there may be water and variations.
실시예 1. 와송 열수추출물 제조Example 1. Wasong hot water extract preparation
와송은 남원에 소재한 영농조합법인으로부터 구매하였다. 와송 건조분말 1kg을 증류수 10L에 넣고 3시간 동안 100℃의 온도로 끓여 추출하였다. 추출물은 동결건조시켜 와송 열수추출물을 완성하였다.Wasong was purchased from the Agricultural Cooperative Corporation located in Namwon. 1 kg of wasong dry powder was put in 10 L of distilled water and extracted by boiling at a temperature of 100° C. for 3 hours. The extract was freeze-dried to complete the Wasong hot water extract.
실시예 2. 와송 주정추출물 제조Example 2. Wasong alcohol extract preparation
와송은 남원에 소재한 영농조합법인으로부터 구매하였다. 와송 건조분말 1kg을 주정 10L에 넣고 균질기(homogenizer)를 이용해 밤새 저으면서 2회에 걸쳐 환류추출하였다. 추출물은 동결건조시켜 와송 주정추출물을 완성하였다.Wasong was purchased from the Agricultural Cooperative Corporation located in Namwon. 1 kg of wasong dry powder was put into 10 L of alcohol, and the mixture was extracted under reflux twice while stirring overnight using a homogenizer. The extract was freeze-dried to complete the Wasong alcohol extract.
실험예 1. 부검 육안소견 및 간 무게, 체중 비교Experimental Example 1. Comparison of necropsy gross findings and liver weight and body weight
1-1. 실험 준비1-1. Experiment preparation
유전적 소인에 의해 제2형 당뇨병이 발현되는 모델인 db/db 마우스와 대조군인 db/+ 5주령 마우스를 각각 24마리, 32마리 입수하여 2주의 순화과정을 거쳐 7주령에 db/+ 마우스는 그룹 당 6마리, db/db 마우스는 그룹 당 8마리 씩 분류하였다. We obtained 24 and 32 db/db mice, a model for expressing
와송 주정추출물 및 열수추출물을 생리식염수에 녹여 주정추출물은 50, 100, 그리고 200 mg/mL, 열수추출물은 100, 200, 그리고 400 mg/ml 농도로 주 5회씩 8-10주 동안 경구 투여를 진행하였다.Dissolve wasong alcohol extract and hot water extract in physiological saline, and administer 50, 100, and 200 mg/mL for alcohol extract and 100, 200, and 400 mg/ml for hot water extract 5 times a week for 8-10 weeks. did.
1-2. 실험 과정1-2. experimental process
실험 기간 10주 후 부검을 실시하였다.After 10 weeks of the experiment, an autopsy was performed.
1-3. 실험 결과1-3. Experiment result
(1) 부검 육안소견 결과(1) Result of autopsy visual findings
당뇨가 유발된 db/db 마우스 그룹에서 db/+ 그룹에 비하여 피하 및 복강 내 지방조직의 크기가 증가된 것을 확인하였다. Compared to the db/+ group in the diabetic db/db mouse group, It was confirmed that the size of adipose tissue in the subcutaneous and abdominal cavity was increased.
반면, 도 1 및 도 2에 도시된 바와 같이 와송 주정추출물 투여에 의한 지방조직이나 간 모양 및 크기의 변화를 확인할 수 없었다. On the other hand, as shown in FIGS. 1 and 2, changes in the shape and size of adipose tissue or liver by the administration of Wasong alcohol extract could not be confirmed.
그리고 도 3 및 도 4에 도시된 바와 같이 와송 열수추출물 투여에 의한 지방조직이 미약하게 감소함을 확인하였으나 간 모양 및 크기의 변화는 확인할 수 없었다.And as shown in FIGS. 3 and 4, it was confirmed that the adipose tissue was slightly decreased by the administration of the Wasong hot water extract, but the change in the shape and size of the liver could not be confirmed.
(2)간 무게 및 체중 측정 결과(2) Liver weight and weight measurement results
당뇨가 유발된 db/db 마우스 그룹에서 db/+ 그룹에 비하여 체중 및 간의 무게가 증가한 결과를 확인하였다. Compared to the db/+ group in the diabetic db/db mouse group, The results of increased body weight and liver weight were confirmed.
반면 도 5 내지 도 7에 도시된 바와 같이 와송 주정추출물 투여에 의하여 체중은 유의성 있게 감소하는 것을 확인하였으나, 간 및 신장 무게의 통계적 유의성은 확인할 수 없었다. 이러한 결과로 와송 주정추출물 투여에 의하여 당뇨 유발 마우스에서 체중감소를 유도함을 확인하였다.On the other hand, as shown in FIGS. 5 to 7 , it was confirmed that the body weight was significantly reduced by administration of the Wasong alcohol extract, but the statistical significance of the liver and kidney weights could not be confirmed. As a result, it was confirmed that the administration of wasong alcohol extract induces weight loss in diabetic mice.
그리고 도 8 및 도 9에 도시된 바와 같이 와송 열수추출물 투여에 의하여 체중은 감소하는 양상은 확인하였으나, 통계적 유의성은 확인할 수 없었다. 도 10에 도시된 바와 같이 간 및 신장 무게 또한 와송 열수추출물의 투여에 의한 변화는 확인할 수 없었다. And as shown in FIGS. 8 and 9 , it was confirmed that the body weight decreased by administration of the Wasong hot water extract, but statistical significance could not be confirmed. As shown in FIG. 10, no change in liver and kidney weights due to administration of wasong hot water extract could be confirmed.
실험예 2. 항당뇨 지표에 대한 영향 평가Experimental Example 2. Evaluation of the effect on the antidiabetic index
2-1. 실험 준비2-1. Experiment preparation
1-1과 같이 마우스를 준비하였다.Mice were prepared as in 1-1.
2-2. 실험 과정2-2. experimental process
1-1의 마우스를 최소 8시간동안 절식한 후 (1)혈중 포도당 수치와 (2)당화혈색소 수치(HbA1c)를 측정하였고, 그 뒤 (3)당(2g/kg 체중)을 경구 투여하고 혈중 포도당 수치를 0, 30, 60, 90, 120분 후 각각 측정하여 혈당 조절 능력을 평가하였다. After fasting for at least 8 hours, (1) blood glucose level and (2) glycated hemoglobin level (HbA1c) were measured for 1-1 mice, and then (3) sugar (2 g/kg body weight) was orally administered and blood glucose level was measured. Glucose levels were measured after 0, 30, 60, 90, and 120 minutes, respectively, to evaluate the ability to control blood sugar.
2-3. 실험 결과2-3. Experiment result
(1)절식 후 혈당측정결과(1) Results of blood glucose measurement after fasting
도 11에 도시된 바와 같이 와송 주정추출물을 투여 받은 당뇨 유발 마우스 그룹에서 혈당이 유의적으로 감소하는 결과를 확인하였다. 이 결과를 바탕으로 초기 혈당수치와 차이를 비교분석 한 결과 혈당의 변화량 역시 와송 주정추출물 투여에 의하여 감소한 결과를 확인하였다.As shown in FIG. 11 , it was confirmed that blood sugar significantly decreased in the diabetic mouse group receiving the Wasong alcohol extract. Based on this result, as a result of comparative analysis of the difference with the initial blood sugar level, it was confirmed that the amount of change in blood sugar was also reduced by the administration of wasong alcohol extract.
그리고 도 12에 도시된 바와 같이 와송 열수추출물을 투여 받은 당뇨 유발 마우스 그룹에서 혈당이 미약하게 감소하는 결과를 확인하였다. 이 결과를 바탕으로 초기 혈당수치와 차이를 비교분석 한 결과 혈당의 변화량 역시 와송 열수추출물 투여에 의하여 미약하게 감소한 결과를 확인하였다.And as shown in FIG. 12 , it was confirmed that the blood glucose level was slightly decreased in the diabetic mouse group receiving the Wasong hot water extract. As a result of comparative analysis of the difference with the initial blood sugar level based on these results, it was confirmed that the amount of change in blood sugar was also slightly decreased by the administration of wasong hot water extract.
(2)당화혈색소(HbA1c) 측정결과(2) Glycated hemoglobin (HbA1c) measurement result
도 11에 도시된 바와 같이 와송 주정추출물을 투여 받은 당뇨 유발 마우스 그룹에서 당화혈색소의 측정값이 유의적으로 감소하는 것을 확인하였다.As shown in FIG. 11 , it was confirmed that the measured value of glycated hemoglobin significantly decreased in the diabetic-induced mouse group receiving the Wasong alcohol extract.
그리고 도 12에 도시된 바와 같이 와송 열수추출물의 고농도를 투여 받은 당뇨 유발 마우스 그룹에서 당화혈색소의 측정값이 유의적으로 감소하는 것을 확인하였다.And, as shown in FIG. 12 , it was confirmed that the measured value of glycated hemoglobin significantly decreased in the diabetic-induced mouse group that received the high concentration of Wasong hot water extract.
(3)경구 당 부하검사결과(oral glucose tolerance test)(3) Oral glucose tolerance test
db/db 마우스 그룹에서 혈당은 120분 후에도 초기 혈당에 비하여 현저히 증가 된 것을 확인하였다. In the db/db mouse group, it was confirmed that blood sugar was significantly increased compared to the initial blood sugar even after 120 minutes.
도 13에 도시된 바와 같이 와송 주정추출물 투여군의 경우, 당 투여 후 시간이 지남에 따라 혈당이 감소하는 유의적으로 감소하는 결과를 확인하였다. 이러한 결과로 와송 주정추출물 투여에 의하여 당뇨 유발 마우스에서 혈당 조절 능력이 개선됨을 나타낸다.As shown in FIG. 13 , in the case of the Wasong alcohol extract administered group, it was confirmed that the blood sugar decreased significantly over time after the administration of the sugar. These results indicate that the blood sugar control ability is improved in diabetic mice by administration of the Wasong alcohol extract.
그리고 도 14에 도시된 바와 같이 와송 열수추출물 투여군의 경우, 투여받지 않은 그룹에 비해 혈당이 유의적으로 감소하는 결과를 확인하였다. 이러한 결과로 와송 열수추출물 투여에 의하여 당뇨 유발 마우스에서 혈당 조절 능력이 개선됨을 나타낸다.And, as shown in FIG. 14 , in the case of the wasong hot water extract administered group, it was confirmed that the blood sugar significantly decreased compared to the non-administered group. These results indicate that the glycemic control ability is improved in diabetic mice by administration of the wasong hot water extract.
실험예 3. 당뇨병에 의한 간 손상 및 지방침착 확인Experimental Example 3. Diabetes-induced liver damage and fat deposition
3-1. 실험 준비3-1. Experiment preparation
1-1.과 같은 방법으로 마우스를 준비하였다.Mice were prepared in the same way as in 1-1.
3-2. 실험 과정3-2. experimental process
3-1의 마우스에서 채취한 혈액시료를 원심분리하여 혈청을 얻고, (1)간 손상 관련 효소인 ALT(alanine aminotransferase), AST(aspartate transaminase) 및 BUN(blood urea nitrogen)을 측정하였고, (2)3-1 마우스에서 채취한 간에서 중성지방(triglyceride, 이하 ‘TG’) 및 총 콜레스테롤의 양(total cholesterol, 이하 ‘TC’)을 측정하였다.Serum was obtained by centrifugation of blood samples collected from mice of 3-1, (1) liver damage-related enzymes ALT (alanine aminotransferase), AST (aspartate transaminase) and BUN (blood urea nitrogen) were measured, (2) ) 3-1 Triglyceride (hereinafter 'TG') and total cholesterol (total cholesterol, hereinafter 'TC') were measured in livers collected from mice.
3-3. 실험 결과3-3. Experiment result
(1)간 손상 수치 측정 결과(1) Results of liver damage measurement
도 15에 도시된 바와 같이 혈청학적 분석을 통하여 와송 주정추출물 투여에 의하여 ALT 및 AST 수치가 유의적으로 감소한 결과를 확인하였다. 이는 당뇨 유발 마우스의 간 손상이 와송 주정추출물 투여에 의하여 감소하는 것을 의미한다.As shown in FIG. 15 , it was confirmed through serological analysis that the ALT and AST levels were significantly decreased by the administration of the Wasong alcohol extract. This means that liver damage in diabetic mice is reduced by the administration of wasong alcohol extract.
혈청학적 분석을 통하여 와송 주정추출물 투여에 의하여 BUN 수치는 차이가 없음을 확인하였다.Through serological analysis, it was confirmed that there was no difference in the BUN level by the administration of Wasong alcohol extract.
그리고 도 16에 도시된 바와 같이 혈청학적 분석을 통하여 와송 열수추출물 투여에 의하여 AST 수치가 유의적으로 감소한 결과를 확인하였다. 그러나 ALT 수치에서는 통계적으로 유의성 있는 결과를 확인할 수 없었다. 이는 당뇨 유발 마우스의 간 손상이 와송 열수추출물 투여에 의하여 감소하는 것을 의미한다.And, as shown in FIG. 16, it was confirmed through serological analysis that the AST level was significantly decreased by the administration of the Wasong hot water extract. However, no statistically significant results were found in the ALT level. This means that liver damage in diabetic mice was reduced by administration of wasong hot water extract.
혈청학적 분석을 통하여 당뇨가 유발된 db/db 마우스 그룹에서 db/+ 그룹에 비하여 증가한 BUN 수치가 와송 열수추출물 투여에 의하여 감소하는 결과를 확인하였다.Through serological analysis, it was confirmed that the BUN level increased in the diabetic db/db mouse group compared to the db/+ group was decreased by the administration of the Wasong hot water extract.
(2)TG 및 TC 측정 결과(2) TG and TC measurement results
도 17에 도시된 바와 같이 간에서 중성지방 및 콜레스테롤의 양을 측정한 결과 와송 주정추출물 투여에 의하여 지방 축적이 유의적으로 감소한 결과를 확인하였다As shown in FIG. 17, as a result of measuring the amount of triglyceride and cholesterol in the liver, it was confirmed that the fat accumulation was significantly reduced by the wasong alcohol extract administration.
그리고 도 18에 도시된 바와 같이 간에서 중성지방 및 콜레스테롤의 양을 측정한 결과 와송 열수추출물 투여에 의하여 지방 축적의 차이를 확인할 수 없었다.And as shown in FIG. 18, as a result of measuring the amounts of triglycerides and cholesterol in the liver, the difference in fat accumulation could not be confirmed by the administration of the Wasong hot water extract.
실험예 4. 간의 조직병리학적 변화 분석Experimental Example 4. Analysis of histopathological changes in the liver
4-1. 실험 준비4-1. Experiment preparation
실험예 1에서 부검된 마우스의 간 조직을 준비하였다.The liver tissue of the mouse autopsied in Experimental Example 1 was prepared.
4-2. 실험 과정4-2. experimental process
포르말린 고정 후 일반적인 처리과정을 거친 조직절편을 H&E 염색을 통하여 당뇨유발에 의한 간의 병리학적 변화를 관찰하였다.After formalin fixation, hepatic pathological changes caused by diabetes were observed through H&E staining of tissue sections that had undergone a general treatment process.
4-3. 실험 결과4-3. Experiment result
와송 주정추출물 투여군의 경우, 도 19에 도시된 바와 같이 간의 H&E 염색 결과 db/db 마우스 군에서 간세포 변성(hepatocellular hypertrophy, ballooning degeneration) 및 지방침착(stratosis)을 관찰할 수 있었으며, 이러한 양상은 와송 주정추출물 투여에 의해 유의적으로 감소되는 것을 확인하였다.In the case of the Wasong alcohol extract administration group, as shown in FIG. 19 , hepatocellular hypertrophy (ballooning degeneration) and stratosis were observed in the db/db mouse group as a result of liver H&E staining, and this aspect is the Wasong alcohol It was confirmed that it was significantly reduced by administration of the extract.
그리고 와송 열수추출물 투여군의 경우, 도 20에 도시된 바와 같이 간의 H&E 염색 결과 db/db 마우스 군에서 간세포 변성 및 지방침착을 관찰할 수 있었으며, 이러한 양상은 와송 열수추출물 투여에 의해 미약하게 감소되는 것을 확인하였다.And in the case of the Wasong hot water extract administration group, as shown in FIG. 20 , hepatocyte degeneration and fat deposition were observed in the db/db mouse group as a result of H&E staining of the liver, and this aspect was slightly reduced by the administration of the Wasong hot water extract. Confirmed.
실험예 5. 췌장의 조직병리학적 변화 분석Experimental Example 5. Analysis of histopathological changes in the pancreas
5-1. 실험 준비5-1. Experiment preparation
실험예 1에서 부검된 마우스의 췌장 조직을 준비하였다.The pancreas tissue of the mouse autopsied in Experimental Example 1 was prepared.
5-2. 실험 과정5-2. experimental process
포르말린 고정 후 일반적인 처리과정을 거친 조직절편을 H&E 염색을 통하여 당뇨유발에 의한 췌장의 병리학적 변화를 관찰하였다.Pathological changes in the pancreas due to diabetes were observed through H&E staining of tissue sections that had undergone a general treatment after formalin fixation.
5-3. 실험 결과5-3. Experiment result
와송 주정추출물 투여군의 경우, 도 21에 도시된 바와 같이 췌장 H&E 염색 결과 인슐린 저항성으로 인한 췌장의 랑게르한스 섬 면적이 현저히 증가한 것이 db/db 마우스 군에서 관찰되었다. 이러한 변화는 와송 주정추출물 투여에 의하여 감소하는 것을 확인하였다. In the case of the Wasong alcohol extract administered group, as shown in FIG. 21 , as a result of pancreatic H&E staining, a marked increase in the area of the islet of Langerhans in the pancreas due to insulin resistance was observed in the db/db mouse group. It was confirmed that these changes were reduced by the administration of wasong alcohol extract.
실험예 6. 신장의 조직병리학적 변화 분석Experimental Example 6. Analysis of histopathological changes in the kidney
6-1. 실험 준비6-1. Experiment preparation
실험예 1에서 부검된 마우스의 신장 조직을 준비하였다.The kidney tissue of the mouse autopsied in Experimental Example 1 was prepared.
6-2. 실험 과정6-2. experimental process
포르말린 고정 후 일반적인 처리과정을 거친 조직절편을 H&E 염색을 통하여 당뇨유발에 의한 신장의 병리학적 변화를 관찰하였다.After formalin fixation, the tissue sections that had undergone the general treatment process were subjected to H&E staining to observe pathological changes in the kidneys due to diabetes induction.
6-3. 실험 결과6-3. Experiment result
와송 주정추출물 투여군의 경우, 도 22에 도시된 바와 같이 염색을 통하여 당뇨 유발 마우스에서 와송 주정추출물 투여에 의한 신장의 조직병리 변화를 관찰한 결과, 신장 사구체의 손상 및 글리코겐 침착에 큰 차이가 없는 결과를 확인하였다.In the case of the Wasong alcohol extract-administered group, as shown in FIG. 22, as a result of observing changes in kidney histopathology by administration of the Wasong alcohol extract in diabetic mice through staining, there was no significant difference in renal glomerular damage and glycogen deposition. was confirmed.
그리고 와송 열수추출물 투여군의 경우, 도 23에 도시된 바와 같이 염색을 통하여 당뇨 유발 마우스에서 와송 열수추출물 투여에 의한 신장의 조직병리 변화를 관찰한 결과, 신장 사구체의 손상 및 글리코겐 침착에 큰 차이가 없는 결과를 확인하였다.And in the case of the wasong hot water extract administration group, as shown in FIG. 23, as a result of observing the change of kidney histopathology by administration of the wasong hot water extract in diabetic mice through staining, there was no significant difference in renal glomerular damage and glycogen deposition. The results were confirmed.
실험예 7. 지방 관련 유전자 발현 분석Experimental Example 7. Fat-related gene expression analysis
7-1. 실험 과정7-1. experimental process
실험예 1에서 부검된 마우스의 간 조직에서 mRNA를 추출하여 cDNA를 합성하였다. 다양한 유전자의 발현 변화를 qRT-PCR을 통해 상대정량분석을 실시하여 와송·여주 복합추출물 의한 유전자 발현양상의 변화를 비교분석하였다.cDNA was synthesized by extracting mRNA from the liver tissue of the mouse autopsied in Experimental Example 1. Relative quantitative analysis was performed on the expression changes of various genes through qRT-PCR to compare and analyze the changes in gene expression patterns caused by the Wasong-Yeoju complex extract.
7-2. 실험 결과7-2. Experiment result
와송 주정추출물 투여군의 경우, 도 24에 도시된 바와 같이 지질대사 관련 인자인 Apo B, LPL, L-FABP, 및 FABP4의 발현을 비교분석한 결과 와송 주정추출물 투여에 의하여 당뇨 유발 마우스의 간장에서 유의적으로 감소하는 결과를 확인하였다.In the case of the Wasong alcohol extract administered group, as shown in FIG. 24, the expression of Apo B, LPL, L-FABP, and FABP4, which are lipid metabolism-related factors, was comparatively analyzed. As a result, it was significant in the liver of diabetic mice by the Wasong alcohol extract administration. A negative decrease was confirmed.
지질생합성(de novo lipogenesis)관련 인자인 ACCα, ACCβ, FASN, 및 SCD1의 발현을 비교분석한 결과 와송 주정추출물 투여에 의하여 당뇨 유발 마우스의 간장에서 유의적으로 감소하는 결과를 확인하였다.As a result of comparative analysis of the expression of ACCα, ACCβ, FASN, and SCD1, which are factors related to lipid biosynthesis ( de novo lipogenesis), it was confirmed that the administration of Wasong alcohol extract significantly decreased the liver of diabetic mice.
이러한 변화와 밀접한 연관이 있는 전자조절인자 및 그 관련 인자인 SREBP-1, SREBP-2, LXRα, 및 LXRβ의 발현을 비교분석한 결과 와송 주정추출물 투여에 의하여 당뇨 유발 마우스의 간장에서 유의적으로 감소하는 결과를 확인하였다. 반면 간 보호 및 항 당뇨효능이 있다고 알려져 있는 PPARα의 발현은 미약하게 증가하는 양상을 확인하였다.As a result of comparative analysis of the expression of electronic regulators closely related to these changes and their related factors, SREBP-1, SREBP-2, LXRα, and LXRβ, it was significantly reduced in the liver of diabetic mice by administration of wasong alcohol extract. The result was confirmed. On the other hand, it was confirmed that the expression of PPARα, which is known to have hepatoprotective and antidiabetic effects, slightly increased.
그리고 와송 열수추출물 투여군의 경우, 도 25에 도시된 바와 같이 지질대사 관련 인자인 L-FABP, ApoB의 발현을 비교분석한 결과 와송 열수추출물 투여에 의하여 ApoB에서 당뇨 유발 마우스의 간장에서 유의적으로 감소하는 결과를 확인하였다.And in the case of the wasong hot water extract administration group, as shown in FIG. 25, as a result of comparative analysis of the expression of L-FABP and ApoB, which are factors related to lipid metabolism, ApoB significantly decreased in the liver of diabetic mice by administration of the wasong hot water extract. The result was confirmed.
지질생합성(de novo lipogenesis)관련 인자인 ACCα, ACCβ, 및 FASN의 발현을 비교분석한 결과 ACCα, ACCβ의 발현이 와송 열수추출물 투여에 의하여 당뇨 유발 마우스의 간장에서 유의적으로 감소하는 결과를 확인하였다.As a result of comparative analysis of the expression of ACCα, ACCβ, and FASN, which are factors related to de novo lipogenesis, it was confirmed that the expression of ACCα and ACCβ was significantly reduced in the liver of diabetic mice by administration of wasong hot water extract. .
이러한 변화와 밀접한 연관이 있는 전자조절인자 및 그 관련 인자인 LXRα, LXRβ의 발현을 비교분석한 결과 와송 열수추출물 투여에 의하여 당뇨 유발 마우스의 간장에서 통계적인 유의성은 확인할수 없었으나 미약하게 감소하는 결과를 확인하였다. 반면 간 보호 및 항 당뇨효능이 있다고 알려져 있는 PPARα의 발현은 미약하게 증가하는 양상을 확인하였다.As a result of comparative analysis of the expression of electronic regulators closely related to these changes and their related factors, LXRα and LXRβ, statistical significance could not be confirmed in the liver of diabetic mice by the administration of hot water extract of Wasong, but it was slightly decreased. was confirmed. On the other hand, it was confirmed that the expression of PPARα, which is known to have hepatoprotective and antidiabetic effects, slightly increased.
실험예 8. 염증 관련 유전자 발현 분석Experimental Example 8. Inflammation-related gene expression analysis
8-1. 실험 과정8-1. experimental process
실험예 1에서 부검된 마우스의 간 조직에서 mRNA를 추출하여 cDNA를 합성하였다. 다양한 유전자의 발현 변화를 qRT-PCR을 통해 상대정량분석을 실시하여 와송·여주 복합추출물 의한 유전자 발현양상의 변화를 비교분석하였다.cDNA was synthesized by extracting mRNA from the liver tissue of the mouse autopsied in Experimental Example 1. Relative quantitative analysis was performed on the expression changes of various genes through qRT-PCR to compare and analyze changes in gene expression patterns caused by the Wasong-Yeoju complex extract.
8-2. 실험 결과8-2. Experiment result
염증관련 대표인자인 TNF-α, IL-6, 및 IL-1β의 발현을 확인해 본 결과, 도 26에 도시된 바와 같이 와송 주정추출물을 투여한 마우스의 간에서 유의적으로 감소하는 결과를 확인하였다. As a result of confirming the expression of TNF-α, IL-6, and IL-1β, which are representative inflammation-related factors, it was confirmed that the result was significantly decreased in the liver of the mice administered the Wasong alcohol extract as shown in FIG. .
이러한 분석 결과를 바탕으로, 와송 주정추출물의 처리가 염증인자의 발현을 억제시킴으로써 간 손상을 감소시킴을 확인하였다.Based on these analysis results, it was confirmed that the treatment of Wasong alcohol extract reduces liver damage by suppressing the expression of inflammatory factors.
실험예 9. 당 대사 관련 유전자 발현 분석Experimental Example 9. Analysis of gene expression related to sugar metabolism
9-1. 실험 과정9-1. experimental process
실험예 1에서 부검된 마우스의 간 조직에서 mRNA를 추출하여 cDNA를 합성하였다. 다양한 유전자의 발현 변화를 qRT-PCR을 통하여 상대정량분석을 실시하여 와송 주정추출물에 의한 유전자 발현양상의 변화를 비교분석하였다.cDNA was synthesized by extracting mRNA from the liver tissue of the mouse autopsied in Experimental Example 1. Relative quantitative analysis was performed on the expression changes of various genes through qRT-PCR to compare and analyze the changes in gene expression patterns caused by the Wasong alcohol extract.
9-2. 실험 결과9-2. Experiment result
와송 주정추출물의 경우, 도 27에 도시된 바와 같이 당 수용체(GLUT2, GLUT4)의 발현을 확인해 본 결과, 당 수용체 발현이 와송 주정추출물 투여에 의하여 유의적인 차이가 없음을 확인하였다.In the case of the Wasong alcohol extract, as shown in FIG. 27 , the expression of the sugar receptors (GLUT2, GLUT4) was confirmed. As a result, it was confirmed that there was no significant difference in the expression of the sugar receptors by the administration of the Wasong alcohol extract.
당 신생합성 관련 유전자(G6Pase, PEPCK)의 발현을 확인해 본 결과, 와송 주정추출물 처리에 의하여 당뇨 유발 마우스 간에서 당 신생합성 관련 유전자인 G6Pase의 발현이 유의적으로 감소하는 결과를 확인하였다.As a result of confirming the expression of gluconeogenesis-related genes (G6Pase, PEPCK), it was confirmed that the expression of G6Pase, a gluconeogenesis-related gene, was significantly decreased in the liver of diabetic mice by the wasong alcohol extract treatment.
이러한 분석 결과를 바탕으로, 와송 주정추출물의 처리가 인슐린 신호전달을 활성화시며, 간장의 당 신생 억제 및 당 유입을 증가시킴으로써 혈당 조절에 좋은 역할을 하는 것을 확인하였다.Based on these analysis results, it was confirmed that the treatment of Wasong alcohol extract activates insulin signaling and plays a good role in glycemic control by inhibiting hepatic gluconeogenesis and increasing glucose inflow.
그리고 와송 열수추출물의 경우, 도 28에 도시된 바와 같이 당 수용체(GLUT2, GLUT4)의 발현을 확인해 본 결과, 당 수용체 발현이 와송 열수추출물 투여에 의하여 유의하게 증가하는 결과를 확인하였다.And in the case of the wasong hot water extract, as shown in FIG. 28, as a result of confirming the expression of the sugar receptors (GLUT2, GLUT4), it was confirmed that the expression of the sugar receptor was significantly increased by administration of the wasong hot water extract.
당 신생합성 관련 유전자(G6Pase)의 발현을 확인해 본 결과, 와송 주정추출물 처리에 의하여 당뇨 유발 마우스 간에서 당 신생합성 관련 유전자인 G6Pase의 발현이 미약하게 감소하는 결과를 확인하였다.As a result of confirming the expression of the gluconeogenesis-related gene (G6Pase), it was confirmed that the expression of G6Pase, a gluconeogenesis-related gene, was slightly decreased in the liver of diabetic mice by the wasong alcohol extract treatment.
이러한 분석 결과를 바탕으로, 와송 주정추출물의 처리가 인슐린 신호전달을 활성화시며, 간장의 당 신생 억제 및 당 유입을 증가시킴으로써 혈당 조절에 좋은 역할을 하는 것을 확인하였다.Based on these analysis results, it was confirmed that the treatment of Wasong alcohol extract activates insulin signaling and plays a good role in glycemic control by inhibiting hepatic gluconeogenesis and increasing glucose inflow.
실험예 10. 항당뇨 효능 Experimental Example 10. Antidiabetic Efficacy in vitroin vitro 평가 evaluation
10-1. 실험 과정10-1. experimental process
간암세포주인 HepG2 cell에 PA를 0.4mM 농도로 처리하거나, High Glucose(4.5g/mL)+Insulin(2.5㎍/mL)을 처리하여 인슐린저항성, 지방 축적 및 세포손상을 유발하였다.HepG2 cells, a hepatocarcinoma cell line, were treated with either PA at a concentration of 0.4 mM or High Glucose (4.5 g/mL) + Insulin (2.5 μg/mL) to induce insulin resistance, fat accumulation and cell damage.
세포독성이 없는 와송 주정추출물의 농도를 확인 후 3가지 농도를 결정하여 처리 후 24시간 배양하였다. After confirming the concentration of wasong alcohol extract without cytotoxicity, three concentrations were determined and cultured for 24 hours after treatment.
다양한 유전자의 발현 변화를 qRT-PCR을 통하여 상대정량분석을 실시하여 와송 주정추출물에 의한 유전자 발현양상의 변화를 세포수준에서 비교분석하였다.Relative quantitative analysis was performed on the expression changes of various genes through qRT-PCR to compare and analyze changes in gene expression patterns caused by the Wasong alcohol extract at the cellular level.
통계적으로 세포독성이 일어나지 않는 3가지 농도(10ng/mL, 100ng/mL, 1μg/mL)를 설정함.Three concentrations (10 ng/mL, 100 ng/mL, and 1 μg/mL) at which cytotoxicity does not occur statistically were established.
10-2. 실험 결과10-2. Experiment result
도 29를 참고하면, 와송 주정추출물의 처리가 PA 또는 High glucose+Insulin이 처리된 간세포에서 GLUT4를 유의적으로 증가시키는 것을 확인하였고, G6Pase의 발현은 High glucose+insulin 모델에서 유의적으로 감소하는 결과를 확인하였다.Referring to FIG. 29 , it was confirmed that the treatment of Wasong alcohol extract significantly increased GLUT4 in hepatocytes treated with PA or high glucose+insulin, and the expression of G6Pase was significantly decreased in the high glucose+insulin model. was confirmed.
와송 주정추출물의 처리가 PA 또는 High glucose+Insulin이 처리된 간세포에서 PPARα의 발현이 증가하는 결과를 확인하였다.It was confirmed that the treatment of Wasong alcohol extract increased the expression of PPARα in hepatocytes treated with PA or high glucose+Insulin.
와송 주정추출물의 처리가 PA 또는 High glucose+Insulin이 처리된 간세포에서 염증인자의 발현을 감소시켜 생체 내 실험결과와 유사함을 확인하였다.It was confirmed that the treatment of Wasong alcohol extract reduced the expression of inflammatory factors in hepatocytes treated with PA or high glucose + Insulin, which was similar to the in vivo experimental results.
이러한 결과를 바탕으로 와송 주정추출물의 항 당뇨 효능이 세포수준에서도 효과적으로 작용함을 확인하였다.Based on these results, it was confirmed that the anti-diabetic effect of Wasong alcohol extract was effective at the cellular level.
Claims (4)
A food composition for preventing or improving diabetes containing Wasong extract as an active ingredient.
상기 와송 추출물은 주정추출물인 것을 특징으로 하는 당뇨 예방 또는 개선용 식품 조성물.
The method according to claim 1,
The Wasong extract is a food composition for preventing or improving diabetes, characterized in that it is an alcohol extract.
상기 당뇨는 2형 당뇨인 것을 특징으로 하는 당뇨 예방 또는 개선용 식품 조성물.
The method according to claim 1,
The diabetes is a food composition for preventing or improving diabetes, characterized in that type 2 diabetes.
A pharmaceutical composition for preventing or treating diabetes containing a Wasong extract as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190167097A KR20210075705A (en) | 2019-12-13 | 2019-12-13 | Composition comprising extracts of Orostachys japonicus as an active ingredient for preventing, alleviating or treating diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190167097A KR20210075705A (en) | 2019-12-13 | 2019-12-13 | Composition comprising extracts of Orostachys japonicus as an active ingredient for preventing, alleviating or treating diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20210075705A true KR20210075705A (en) | 2021-06-23 |
Family
ID=76599239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190167097A KR20210075705A (en) | 2019-12-13 | 2019-12-13 | Composition comprising extracts of Orostachys japonicus as an active ingredient for preventing, alleviating or treating diabetes |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20210075705A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101685581B1 (en) | 2015-08-12 | 2016-12-12 | 김수경 | Compositions for improving skin wrinkle or moisture comprising Orostachys japonicus and composition prepared therefrom |
KR20190082704A (en) | 2019-07-01 | 2019-07-10 | 인제대학교 산학협력단 | Composition for repressing or removing Staphylococcus spp. biofilm comprising the extract of Orostachys japonicas |
-
2019
- 2019-12-13 KR KR1020190167097A patent/KR20210075705A/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101685581B1 (en) | 2015-08-12 | 2016-12-12 | 김수경 | Compositions for improving skin wrinkle or moisture comprising Orostachys japonicus and composition prepared therefrom |
KR20190082704A (en) | 2019-07-01 | 2019-07-10 | 인제대학교 산학협력단 | Composition for repressing or removing Staphylococcus spp. biofilm comprising the extract of Orostachys japonicas |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101277710B (en) | Antiobesity composition | |
Gohil et al. | Treatment with extracts of Eugenia jambolana seed and Aegle marmelos leaf extracts prevents hyperglycemia and hyperlipidemia in alloxan induced diabetic rats | |
Luo et al. | Sweet potato (Ipomoea batatas L.) leaf polyphenols ameliorate hyperglycemia in type 2 diabetes mellitus mice | |
Thomas et al. | The significance of Tinospora crispa in treatment of diabetes mellitus | |
KR101090319B1 (en) | A composition having an effect of curing and preventing diabetes mellitus | |
Wang et al. | p-Synephrine ameliorates alloxan-induced diabetes mellitus through inhibiting oxidative stress and inflammation via suppressing the NF-kappa B and MAPK pathways | |
Onaolapo et al. | Ocimum Gratissimum Linn causes dose dependent hepatotoxicity in streptozotocin-induced diabetic Wistar rats | |
CN101336974B (en) | Traditional Chinese medicine for reducing blood sugar and regulating lipid with overall regulation of body metabolism and preparation method thereof | |
KR100831621B1 (en) | The plant extracts composition for the blood glucose reducing action | |
US20030232099A1 (en) | Health-care products and methods for preparing and using the same | |
CN101856418A (en) | Pharmaceutical preparation for preventing nephritis and preparation method thereof | |
KR20210075705A (en) | Composition comprising extracts of Orostachys japonicus as an active ingredient for preventing, alleviating or treating diabetes | |
CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
CN101926852A (en) | Application of roots and leaves of common fig in preparing auxiliary therapy medicine and health food for hepatitis | |
KR102488212B1 (en) | Orostachys japonicas and Momordica charantia Linn complex-extract for improving blood sugar and method of manufacturing the same | |
KR101303541B1 (en) | A composition having effects of preventing alcoholic liver damage and alcoholic fat liver and of ameliorating hangover | |
CN113068832A (en) | A health product with effects of nourishing liver and kidney, fixing hair, and preventing alopecia, and its preparation method | |
KR20100111088A (en) | Composition for preventing and treating diabetes mellitus or diabetic complications comprising extract of herbal combination | |
Pochhi | An antioxidant activity of Cinnamonum tamala improves histopathological alterations and biochemical parameters in alloxan induced diabetic rats | |
CN101269152A (en) | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament | |
CN106215043A (en) | A kind of roxburgh anoectochilus terminal bud buccal tablet with effect of lowering blood sugar and preparation method thereof | |
CN109966283A (en) | Application of the degreasing cinnamon polyphenol extract in preparation prevention and treatment diabetic nephropathy product | |
Mirsky | Glucose tolerance factor–insulin mimetic and potentiating agent–a source for a novel anti diabetic medication | |
Helal et al. | Ameliorative effects of artemisia judaica l. extract against alloxan-induced biochemical alterations in male wistar rats | |
Nadro et al. | Anti-diabetic effects of aqueous extract and oil of Moringa oleifera seed on liver and kidney functions in Streptozotocin-induced diabetes in Rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X601 | Decision of rejection after re-examination | ||
J201 | Request for trial against refusal decision | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2023101000057; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230109 Effective date: 20231114 |